Table 2 Outcomes at end of study (median time of 134 weeks)

HIV-related illness

   No. patient (%)

4 (16.7)

-

0.118

Adverse events

   No. patient (%)

22 (91.7)

19 (100)

0.495

   No. event (% per month)

100 (13.3)

97 (17.0)

0.081

ARV-related adverse events

   No. patient (%)

7 (29.2)

4 (21.1)

0.728

   No. event (% per month)

10 (1.3)

5 (0.7)

0.467

Median weight for age Z-scores (IQR)

-1.1 (-1.5 to -0.8)

-1.0 (-1.7 to 0.2)

0.525

Median height for age Z-scores (IQR)

-1.4 (-2.0 to -0.8)

-0.8 (-1.3 to -0.4)

0.171

Median CD4% (IQR)

31 (24 – 39)

23 (17 – 31)

0.032

Median CD4% change (IQR)

13.5 (4 – 18)

3 (-2 to 13)

0.012

Median viral load*, log (IQR)

1.7 (1.7 – 2.5)

3.1 (1.7 – 4.5)

0.039

Median change viral load, log (IQR)

-2.8 (-3.4 to -1.9)

-1.8 (-3.2 to -0.3)

0.079

Median Hemoglobin, g/dL (IQR)

11.7 (10.9 – 12.5)

11.7 (10.9 – 12.5)

0.961

Median alanine transferase, unit/mL (IQR)

15 (12.3 – 21.8)

18 (14 – 23)

0.418

Median triglyceride, mg/dL (IQR)

72 (46 – 109)

98 (61 – 156)

0.106

Median cholesterol, mg/dL (IQR)

158 (152 – 202)

160 (143 – 180)

0.197

Median glucose, mg/dL (IQR)

77 (67 – 87)

76.5 (72.3 – 90.5)

0.833